1
|
Gallo V, Alessi E, Montilla S, Altamura G, Traversa G, Trotta F. The timelines for the price and reimbursement authorization in Italy 2018-2020. Front Med (Lausanne) 2022; 9:1055359. [PMID: 36619645 PMCID: PMC9810802 DOI: 10.3389/fmed.2022.1055359] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2022] [Accepted: 11/25/2022] [Indexed: 12/24/2022] Open
Abstract
Objective This investigation aimed to guarantee the principles of transparency in public administration; to inform citizens about the time to patient access to reimbursed medicines; to assess the duration of the P&R process for the first time in the period 2018-2020; and to evaluate whether and how the SARS-CoV-2 (COVID-19) pandemic affected the P&R activity. This study analyzed the timelines of pricing and reimbursement procedures submitted in Italy by the pharmaceutical marketing authorization holder (MAH) from 2018 to 2020. Methods The analysis was run through an AIFA web-based platform that collects data about P&R procedures for each step of the Italian Price and Reimbursement (P&R) procedure, including dates of the Technical Scientific Committee (CTS) and Price and Reimbursement Committee (CPR) meetings from January 2018 to December 2020. On this basis, four indicators were developed relating to the completion time of each stage of the P&R negotiation process and were defined in terms of days. In this regard, descriptive analyses, graphical boxplots, and survival curves (Kaplan-Meier) were carried out, studying these indicators in relation to the typology of pharmaceutical procedures. Results Overall, in the period 2018-2020, 57.1% of the 2,445 procedures entered were represented by the Off-patent pharmaceuticals procedures (generics, biosimilars, copies, and/or parallel trade). In 2020, the overall process duration for Off-patent pharmaceuticals procedures was equal to 129.8 average days [95% CI: (122.3-137.2)], with a median value of 108.0, whereas for In-patent pharmaceuticals procedures, it was equal to 283.1 average days [95% CI: (267.8-298.5)], with a median value of 284.0. Over time, the trend of the entire duration of the P&R process tended to decrease. In terms of estimated timing for the conclusion of each stage of the P&R negotiation process, the difference between Off-patent and In-patent pharmaceutical procedures was statistically significant by the Log-Rank test. Discussion and conclusion This is the first study to examine the time of the P&R process in Italy, from MAH submission to the publication of the final decision in the Italian Official Journal. The time span considered is 3 years, including the first year of the COVID-19 pandemic. Compared to European average times, in Italy, the time necessary for evaluation, authorization for reimbursement, and definition of the price of a medicine can be considered satisfactory.
Collapse
|
2
|
Mennini FS, Marcellusi A, Robbins Scott S, Montilla S, Craxi A, Buti M, Gheorghe L, Ryder S, Kondili LA. The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries. Liver Int 2021; 41:934-948. [PMID: 33529499 PMCID: PMC8248004 DOI: 10.1111/liv.14808] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 01/21/2021] [Accepted: 01/24/2021] [Indexed: 12/11/2022]
Abstract
BACKGROUND AND AIMS We assessed the clinical and economic impact of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) in England, Italy, Romania and Spain. METHODS An HCV progression Markov model was developed considering DAA eligibility and population data during the years 2015-2019. The period of time to recover the investment in DAAs was calculated as the cost saved by avoiding estimated clinical events for 1000 standardized treated patients. A delayed treatment scenario because of coronavirus disease (COVID-19) was also developed. RESULTS The estimated number of avoided hepatocellular carcinoma, decompensated cirrhosis and liver transplantations over a 20-year time horizon was: 1,057 in England; 1,221 in Italy; 1,211 in Romania; and 1,103 in Spain for patients treated during 2015-2016 and 640 in England; 626 in Italy; 739 in Romania; and 643 in Spain for patients treated during 2017-2019. The cost-savings ranged from € 45 to € 275 million. The investment needed to expand access to DAAs in 2015-2019 is estimated to be recovered in 6.5 years in England; 5.4 years in Italy; 6.7 years in Romania; and 4.5 years in Spain. A delay in treatment because of COVID-19 will increase liver mortality in all countries. CONCLUSION Direct-acting antivirals have significant clinical benefits and can bring substantial cost-savings over the next 20 years, reaching a Break-even point in a short period of time. When pursuing an exit strategy from strict lockdown measures for COVID-19, providing DAAs should remain high on the list of priorities in order to maintain HCV elimination efforts.
Collapse
Affiliation(s)
- Francesco S. Mennini
- Economic Evaluation and HTACentre for Economic and International Studies(EEHTA‐CEIS) Faculty of EconomicsUniversity of Rome “Tor Vergata”RomeItaly,Institute of Leadership and Management in HealthKingston Business SchoolKingston UniveristyLondonUK
| | - Andrea Marcellusi
- Economic Evaluation and HTACentre for Economic and International Studies(EEHTA‐CEIS) Faculty of EconomicsUniversity of Rome “Tor Vergata”RomeItaly,Institute of Leadership and Management in HealthKingston Business SchoolKingston UniveristyLondonUK
| | - Sarah Robbins Scott
- Economic Evaluation and HTACentre for Economic and International Studies(EEHTA‐CEIS) Faculty of EconomicsUniversity of Rome “Tor Vergata”RomeItaly
| | - Simona Montilla
- Department of Economic Strategy of Pharmaceutical ProductsItalian Medicines AgencyRomeItaly
| | - Antonio Craxi
- Gastroenterology and Hepatology UnitDepartment of Internal Medicine and Medical Specialties "PROMISE"University of PalermoPalermoItaly
| | - Maria Buti
- Liver UnitHospital Universitario Valle Hebron and CIBER‐EHD del Insitituto Carlos IIIBarcelonaSpain
| | - Liana Gheorghe
- Center for Digestive Diseases and Liver TransplantationFundeni Clinical InstituteUniversity of Medicine and Pharmacy Carol DavilaBucharestRomania
| | - Stephen Ryder
- NIHR Nottingham Biomedical Research CentreNottingham University Hospitals NHS TrustThe University of NottinghamNottinghamUK
| | | |
Collapse
|
3
|
Kondili LA, Robbins S, Blach S, Gamkrelidze I, Zignego AL, Brunetto MR, Raimondo G, Taliani G, Iannone A, Russo FP, Santantonio TA, Zuin M, Chessa L, Blanc P, Puoti M, Vinci M, Erne EM, Strazzabosco M, Massari M, Lampertico P, Rumi MG, Federico A, Orlandini A, Ciancio A, Borgia G, Andreone P, Caporaso N, Persico M, Ieluzzi D, Madonia S, Gori A, Gasbarrini A, Coppola C, Brancaccio G, Andriulli A, Quaranta MG, Montilla S, Razavi H, Melazzini M, Vella S, Craxì A. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? Liver Int 2018; 38:2190-2198. [PMID: 29900654 PMCID: PMC6282782 DOI: 10.1111/liv.13901] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Accepted: 06/03/2018] [Indexed: 12/13/2022]
Abstract
BACKGROUND & AIMS Advances in direct-acting antiviral treatment of HCV have reinvigorated public health initiatives aimed at identifying affected individuals. We evaluated the possible impact of only diagnosed and linked-to-care individuals on overall HCV burden estimates and identified a possible strategy to achieve the WHO targets by 2030. METHODS Using a modelling approach grounded in Italian real-life data of diagnosed and treated patients, different linkage-to-care scenarios were built to evaluate potential strategies in achieving the HCV elimination goals. RESULTS Under the 40% linked-to-care scenario, viraemic burden would decline (60%); however, eligible patients to treat will be depleted by 2025. Increased case finding through a targeted screening strategy in 1948-1978 birth cohorts could supplement the pool of diagnosed patients by finding 75% of F0-F3 cases. Under the 60% linked-to-care scenario, viraemic infections would decline by 70% by 2030 but the patients eligible for treatment will run out by 2028. If treatment is to be maintained, a screening strategy focusing on 1958-1978 birth cohorts could capture 55% of F0-F3 individuals. Under the 80% linked-to-care scenario, screening limited in 1968-1978 birth cohorts could sustain treatment at levels required to achieve the HCV elimination goals. CONCLUSION In Italy, which is an HCV endemic country, the eligible pool of patients to treat will run out between 2025 and 2028. To maintain the treatment rate and achieve the HCV elimination goals, increased case finding in targeted, high prevalence groups is required.
Collapse
Affiliation(s)
| | - Sarah Robbins
- Center for Disease AnalysisCDA Foundation | Polaris ObservatoryLafayetteCOUSA
| | - Sarah Blach
- Center for Disease AnalysisCDA Foundation | Polaris ObservatoryLafayetteCOUSA
| | - Ivane Gamkrelidze
- Center for Disease AnalysisCDA Foundation | Polaris ObservatoryLafayetteCOUSA
| | - Anna L. Zignego
- Department of Experimental and Clinical MedicineInterdepartmental Centre MASVEUniversity of FlorenceFlorenceItaly
| | - Maurizia R. Brunetto
- Internal MedicineDepartment of Clinical and Experimental Medicine University of Pisa and Liver UnitPisa University HospitalPisaItaly
| | - Giovanni Raimondo
- Department of Internal MedicineUniversity Hospital of MessinaMessinaItaly
| | - Gloria Taliani
- Infectious and Tropical Diseases UnitUmberto I HospitalSapienza UniversityRomeItaly
| | - Andrea Iannone
- Department of GastroenterologyUniversity Hospital of BariBariItaly
| | | | | | - Massimo Zuin
- Liver and Gastroenterology UnitASST Santi Paolo e CarloMilanItaly
| | | | - Pierluigi Blanc
- Department of Infectious DiseaseS.M. Annunziata HospitalFlorenceItaly
| | - Massimo Puoti
- Department of Infectious DiseaseNiguarda HospitalMilanItaly
| | | | - Elke M. Erne
- Department of Infectious DiseaseUniversity Hospital of PaduaPaduaItaly
| | | | - Marco Massari
- Department of Infectious DiseaseArcispedale Santa Maria NuovaReggio EmiliaItaly
| | - Pietro Lampertico
- Department of Gastroenterology and HepatologyFondazione IRCCS Cà Granda Ospedale Maggiore PoliclinicoUniversity of MilanMilanItaly
| | - Maria G. Rumi
- Department of Gastroenterology and HepatologySan Giuseppe HospitalMilanItaly
| | - Alessandro Federico
- Department of Hepatology and GastroenterologyUniversità della Campania Luigi VanvitelliNaplesItaly
| | | | - Alessia Ciancio
- Gastoenterology UnitCittà della Salute e della Scienza‐Ospedale MolinetteTurinItaly
| | - Guglielmo Borgia
- Department of Infectious DiseaseFederico II UniversityNaplesItaly
| | | | | | - Marcello Persico
- Department of Internal Medicine and HepatologyUniversity of SalernoSalernoItaly
| | | | | | - Andrea Gori
- Department of Infectious DiseaseSan Gerardo HospitalMonzaItaly
| | - Antonio Gasbarrini
- Department of Internal Medicine and GastroenterologyCatholic University of RomeRomeItaly
| | | | - Giuseppina Brancaccio
- Infectious DiseasesDepartment of Mental and Physical Health and Preventive MedicineUniversità della Campania Luigi VanvitelliNaplesItaly
| | - Angelo Andriulli
- Division of GastroenterologyIstituto di Ricovero e Cura a Carattere ScientificoCasa Sollievo Sofferenza HospitalSan Giovanni Rotondo, FoggiaItaly
| | | | | | - Homie Razavi
- Center for Disease AnalysisCDA Foundation | Polaris ObservatoryLafayetteCOUSA
| | | | - Stefano Vella
- Center for Global HealthIstituto Superiore di SanitàRomeItaly
| | - Antonio Craxì
- Gastroenterolgy and Liver UnitDiBiMISUniversity of PalermoPalermoItaly
| | | |
Collapse
|
4
|
Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marzioni M, Giannini EG, Craxì A. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. Infection 2018; 46:607-615. [PMID: 29808463 DOI: 10.1007/s15010-018-1157-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2018] [Accepted: 05/22/2018] [Indexed: 02/07/2023]
Abstract
PURPOSE To analyse safety and efficacy of treatment based on ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in the sub-group of GT1 patients older than 65 years. METHODS We collected data extracted from the ABACUS compassionate-use nationwide Italian programme, in patients with cirrhosis due to hepatitis C virus (HCV) Genotype-1 (GT1) or 4 and at high risk of decompensation. GT1-HCV-infected patients received once-daily ombitasvir/paritaprevir, with the pharmacokinetic enhancer ritonavir (25/150/100 mg) and twice-daily dasabuvir (250 mg) plus Ribavirin (RBV) (OBV/PTV/r + DSV + RBV) for 12 (GT1b) or 24 (GT1a) weeks. Endpoints were to evaluate safety and efficacy, the latter defined as HCV RNA negative 12 weeks after the end of treatment (SVR12). RESULTS Patients who suffered any adverse event (AE) were 74/240 (30.8%); 13/240 (5.4%) discontinued the treatment. A multivariate analysis found albumin < 3.5 g/dL (OR 2.04: 95% CI 1.0-4.2, p < 0.05) and hypertension (OR 4.6: 95% CI 2.3-9.2, p < 0.001) as variables independently associated with AE occurrence. The SVR12 was 95% (228/240). Multivariate analysis identified baseline bilirubin < 2 mg/dL (OR 4.9: 95% CI 1.17-20.71, p = 0.029) as the only variable independently associated with SVR12. CONCLUSION Our findings suggest that OBV/PTV/r + DSV + RBV is safe and effective in real-life use in patients with compensated cirrhosis, HCV-GT1 infection, and age over 65.
Collapse
Affiliation(s)
- Antonio Ascione
- Department of Medicine, Centre for Liver Disease, Buon Consiglio-Fatebenefratelli Hospital, Via Manzoni 220, 80123, Naples, Italy.
| | | | | | | | | | - Salvatore Petta
- Department of Gastroenterology, DiBiMIS, University of Palermo, Palermo, Italy
| | - Massimo Puoti
- Division of Infectious Diseases, AO Niguarda Ca' Granda Hospital, Milan, Italy
| | | | | | - Savino Bruno
- Humanitas University and IRCCS Clinical Institute Humanitas, Rozzano, Milan, Italy
| | - Antonio Izzi
- Infectious Disease, Cotugno Hospital, AORN Ospedali dei Colli, Naples, Italy
| | - Erica Villa
- Gastroenterology Unit, Department of Internal Medicine, AOU Policlinico of Modena, Modena, Italy
| | - Alessio Aghemo
- UO Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Hospital Maggiore Policlinico of Milan, Milan, Italy
| | - Anna Linda Zignego
- Interdepartmental Centre for Systemic Manifestations of Hepatitis Viruses (MaSVE), Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | | | - Luca Fontanella
- Department of Medicine, Centre for Liver Disease, Buon Consiglio-Fatebenefratelli Hospital, Via Manzoni 220, 80123, Naples, Italy
| | - Antonio Gasbarrini
- Internal Medicine, Gastroenterology and Hepatology, Agostino Gemelli Hospital, Rome, Italy
| | - Marco Marzioni
- Clinic of Gastroenterology and Hepatology, Università Politecnica delle Marche, Ancona, Italy
| | - Edoardo G Giannini
- Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy
| | - Antonio Craxì
- Department of Gastroenterology, DiBiMIS, University of Palermo, Palermo, Italy
| | | |
Collapse
|
5
|
Villa F, Jommi C, Genazzani A, Antignani S, Montilla S, Melazzini M. Accesso precoce al mercato: dalle approvazioni condizionate di EMA agli accordi negoziali particolari di AIFA. Global & Regional Health Technology Assessment 2018. [DOI: 10.1177/2284240318792447] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Affiliation(s)
- Federico Villa
- Agenzia Italiana del Farmaco, Roma, Italy
- Universiti degli Studi del Piemonte Orientale “Amedeo Avogadro”, Italy
| | - Claudio Jommi
- Universiti degli Studi del Piemonte Orientale “Amedeo Avogadro”, Italy
| | - Armando Genazzani
- Universiti degli Studi del Piemonte Orientale “Amedeo Avogadro”, Italy
| | | | | | | |
Collapse
|
6
|
Martini S, Donato MF, Mazzarelli C, Rendina M, Visco-Comandini U, Filì D, Gianstefani A, Fagiuoli S, Melazzini M, Montilla S, Pani L, Petraglia S, Russo P, Trotta MP, Carrai P, Caraceni P. The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience. Liver Int 2018; 38:733-741. [PMID: 28921807 DOI: 10.1111/liv.13588] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2017] [Accepted: 09/08/2017] [Indexed: 12/16/2022]
Abstract
BACKGROUND & AIMS This study aimed to assess the real-life clinical and virological outcomes of HCV waitlisted patients for liver transplantation (LT) who received sofosbuvir/ribavirin (SOF/R) within the Italian compassionate use program. METHODS Clinical and virological data were collected in 224 patients with decompensated cirrhosis and/or hepatocellular carcinoma (HCC) receiving daily SOF/R until LT or up a maximum of 48 weeks. RESULTS Of 100 transplanted patients, 51 were HCV-RNA negative for >4 weeks before LT (SVR12: 88%) and 49 negative for <4 weeks or still viraemic at transplant: 34 patients continued treatment after LT (bridging therapy) (SVR12: 88%), while 15 stopped treatment (SVR12: 53%). 98 patients completed SOF/R without LT (SVR12: 73%). In patients with advanced decompensated cirrhosis (basal MELD ≥15 and/or C-P ≥B8), a marked improvement of the scores occurred in about 50% of cases and almost 20% of decompensated patients without HCC reached a condition suitable for inactivation and delisting. CONCLUSIONS These real-life data indicate that in waitlisted patients: (i) bridging antiviral therapy can be an option for patients still viraemic or negative <4 weeks at LT; and (ii) clinical improvement to a condition suitable for delisting can occur even in patients with advanced decompensated cirrhosis.
Collapse
Affiliation(s)
- Silvia Martini
- Gastrohepatology Unit, AOU Città della Salute e della Scienza di Torino, Turin, Italy
| | - Maria Francesca Donato
- First Division of Gastroenterology, IRCCS Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy
| | - Chiara Mazzarelli
- Hepatology and Gastroenterology Unit, Niguarda Ca' Granda Hospital, Milan, Italy
| | - Maria Rendina
- Gastroenterology and Digestive Endoscopy, University Hospital, Bari, Italy
| | - Ubaldo Visco-Comandini
- Infectious Diseases - Hepatology Division, National Institute for Infectious Diseases Spallanzani IRCSS, Rome, Italy
| | - Daniela Filì
- Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, Hepatology Unit, IRCCS - ISMETT (Mediterranean Institute for Transplantation and Advanced Specialized Therapies), Palermo, Italy
| | - Alice Gianstefani
- Department of Surgical and Medical Sciences, University of Bologna, Bologna, Italy
| | - Stefano Fagiuoli
- Gastroenterology and Transplant Hepatology, Ospedale Papa Giovanni XXIII di Bergamo, Bergamo, Italy
| | | | | | - Luca Pani
- Italian Medicines Agency (AIFA), Rome, Italy
| | | | | | | | - Paola Carrai
- Hepatobiliary Surgery and Liver Transplantation, University of Pisa, Pisa, Italy
| | - Paolo Caraceni
- Department of Surgical and Medical Sciences, University of Bologna, Bologna, Italy
| | | |
Collapse
|
7
|
Carrai P, Morelli C, Cordone G, Romano A, Tamé M, Lionetti R, Pietrosi G, Lenci I, Piai G, Russo FP, Coppola C, Melazzini M, Montilla S, Pani L, Petraglia S, Russo P, Trotta MP, Martini S, Toniutto P. The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. Transpl Int 2017; 30:1253-1265. [PMID: 28799277 DOI: 10.1111/tri.13018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2017] [Revised: 04/05/2017] [Accepted: 07/27/2017] [Indexed: 12/14/2022]
Abstract
Direct antivirals are available for treating recurrent hepatitis C (RHC). This study reported outcomes of 424 patients with METAVIR F3-F4 RHC who were treated for 24 weeks with sofosbuvir/ribavirin and followed for 12 weeks within the Italian sofosbuvir compassionate use program. In 55 patients, daclatasvir or simeprevir were added. Child-Pugh class and model of end stage liver disease (MELD) scores were evaluated at baseline and 36 weeks after the start of therapy. The sustained viral response (SVR) was 86.7% (316/365) in patients who received sofosbuvir/ribavirin and 98.3% (58/59) in patients who received a second antiviral (P < 0.01). In patients treated with sofosbuvir/ribavirin, a significant difference in SVR was observed between patients diagnosed with METAVIR F4 (211/250; 84.4%), METAVIR F3 (95/105; 90.5%) and fibrosing cholestatic hepatitis (10/10; 100%) (P = 0.049). A significant association was found between patients who worsened from Child-Pugh class A and who experienced viral relapse (4/26 vs. 8/189, P = 0.02). In patients with a baseline MELD score <15, a significant association was found between maintaining a final MELD score <15 and the achievement of SVR (187/219 vs. 6/10, P = 0.031). This real-world study indicates that sofosbuvir/ribavirin treatment for 24 weeks was effective, and the achievement of SVR was associated with a reduced probability of developing worsening liver function.
Collapse
Affiliation(s)
- Paola Carrai
- Liver Surgery and Liver Transplantation, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
| | - Cristina Morelli
- Department of Care of Organ Failures and Transplants, Internal Medicine for the Treatment of Severe Organ Failures, University Hospital - Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - Gabriella Cordone
- Hepatology Unit, Liver Transplant Department, Cardarelli Hospital, Naples, Italy
| | - Antonietta Romano
- Unit of internal Medicine and Hepatology (UIMH), University of Padua, Rome, Italy
| | - Mariarosa Tamé
- Gastroenterology Unit, University Hospital - Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - Raffaella Lionetti
- Infectious Diseases-Hepatology, National Institute for Infectious Diseases Spallanzani, Rome, Italy
| | - Giada Pietrosi
- Hepatology Unit, Department of Medicine, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS-ISMETT), Palermo, Italy
| | - Ilaria Lenci
- Hepatology and Transplant Unit, Department of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy
| | - Guido Piai
- Hepatology Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy
| | - Francesco Paolo Russo
- Gastroenterology/Multivisceral Transplant Unit, University Hospital Padua, Padua, Italy
| | - Carmine Coppola
- Internal Medicine and Liver Unit, Gragnano Hospital (NA), Udine, Italy
| | | | | | - Luca Pani
- Italian Drug Agency (AIFA), Roma, Italy
| | | | | | | | - Silvia Martini
- Gastrohepatology Unit, AOU Città della Salute e della Scienza di Torino, Turin, Italy
| | - Pierluigi Toniutto
- Department of Medical Area (DAME), Medical Liver Transplant Section, Internal Medicine, Azienda Ospedaliero-Universitaria, Udine, Italy
| | | |
Collapse
|
8
|
Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol 2017; 2:427-434. [PMID: 28497758 DOI: 10.1016/s2468-1253(17)30048-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/18/2016] [Revised: 12/23/2016] [Accepted: 01/24/2017] [Indexed: 02/07/2023]
Abstract
BACKGROUND We ran a compassionate use nationwide programme (ABACUS) to provide access to ombitasvir, paritaprevir, and ritonavir, with dasabuvir, plus ribavirin for hepatitis C virus (HCV) genotype 1 infection and ombitasvir, paritaprevir, and ritonavir, plus ribavirin for HCV genotype 4 infection in patients with cirrhosis at high risk of decompensation while approval of these regimens was pending in Italy. METHODS In this prospective observational study, we collected data from a compassionate use nationwide programme from March 17, 2014, to May 28, 2015. Patients with HCV genotype 1 infection and cirrhosis at high risk of decompensation were given coformulated ombitasvir (25 mg), paritaprevir (150 mg), and ritonavir (100 mg) once daily and dasabuvir (250 mg) twice daily for 12 weeks (patients with HCV genotype 1b infection) or 24 weeks (patients with HCV genotype 1a infection). Patients with HCV genotype 4 infection were given coformulated ombitasvir (25 mg), paritaprevir (150 mg), and ritonavir (100 mg) once per day for 24 weeks. All patients were given weight-based ribavirin. The primary efficacy endpoint was sustained virological response at week 12 after the end of treatment (SVR12), analysed by intention-to-treat. Univariate and multivariate logistic regression analyses were used to identify baseline characteristics associated with SVR12. Adverse events were recorded throughout the study. FINDINGS 728 (96%) of 762 patients with cirrhosis who were given ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin therapy for 12 or 24 weeks achieved SVR12. Logistic regression analyses identified that bilirubin concentrations of less than 2 mg/dL were associated with SVR12 (odds ratio [OR] 4·76 [95% CI 1·83-12·3]; p=0·001). 166 (23%) of 734 patients included in safety analyses had an adverse event. 25 (3%) patients discontinued treatment because of adverse events. Asthenia was the most commonly reported adverse event, occurring in 36 (5%) patients. INTERPRETATION Our findings suggest that the safety and effectiveness of ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin in patients with HCV genotype 1 or 4 infection and cirrhosis at high risk of decompensation in a real-life setting are similar to those reported in clinical trials. The concordance with clinical trials provides reassurance that the reported efficacy of this treatment in clinical trials will translate to its use in routine clinical practice. FUNDING Dipartimento Biomedico di Medicina Interna e Specialistica dell'Universita di Palermo.
Collapse
Affiliation(s)
- Salvatore Petta
- Section of Gastroenterology and Hepatology, Biomedical Department of Internal and Specialized Medicine (DiBiMIS), University of Palermo, Palermo, Italy.
| | - Marco Marzioni
- Clinic of Gastroenterology and Hepatology, Università Politecnica delle Marche, Ancona, Italy
| | | | - Alessio Aghemo
- L'Unità Operativa Gastroenterologia ed Epatologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy
| | - Alfredo Alberti
- Department of Molecular Medicine, University of Padova, Padova, Italy
| | - Antonio Ascione
- Centro per le malattie del Fegato, Ospedale Fatebenefratelli, Napoli, Italy
| | - Andrea Antinori
- National Institute for Infectious Diseases, "Lazzaro Spallanzani" Istituto di Ricovero e Cura a Carattere Scientific (IRCCS), Rome, Italy
| | - Raffaele Bruno
- Dipartimento Malattie Infettive, Fondazione IRCCS Policlinico San Matteo Pavia Italia, Università degli studi di Pavia, Pavia, Italy
| | - Savino Bruno
- Humanitas University and Humanitas Research Hospital Rozzano, Milan, Italy
| | - Antonio Chirianni
- UOC Infezioni sistemiche e dell'immunodepresso, AO Ospedali dei Colli Napoli, Napoli, Italy
| | | | - Edoardo G Giannini
- Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy
| | - Manuela Merli
- Gastroenterology Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy
| | - Vincenzo Messina
- Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy
| | | | - Carlo Federico Perno
- Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy
| | - Massimo Puoti
- Department of Infectious Diseases, AO Niguarda Ca' Granda, Milan, Italy
| | - Giovanni Raimondo
- Division of Clinical and Molecular Hepatology, Department of Clinical and Experimental Medicine, University Hospital of Messina, Messina, Italy
| | - Maria Rendina
- Gastroenterology and Digestive Endoscopy, University Hospital Policlinico Bari, Bari, Italy
| | | | - Erica Villa
- Division of Gastroenterology, Azienda Ospedaliero, Universitaria Policlinico di Modena, Italy Università degli Studi di Modena e Reggio Emilia, Modena, Italy
| | - Anna Linda Zignego
- Interdepartmental Centre MASVE, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | - Luca Pani
- Italian Medicines Agency, Rome, Italy
| | - Antonio Craxì
- Section of Gastroenterology and Hepatology, Biomedical Department of Internal and Specialized Medicine (DiBiMIS), University of Palermo, Palermo, Italy
| | | | | |
Collapse
|
9
|
Pani L, Montilla S, Németh G, Russo P, Viceconte G, Vogler S. Balancing access to medicines and sustainability in Europe: An analysis from the network of competent authorities on pricing and reimbursement (CAPR). Pharmacol Res 2016; 111:247-250. [PMID: 27293051 DOI: 10.1016/j.phrs.2016.05.022] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2016] [Revised: 04/29/2016] [Accepted: 05/03/2016] [Indexed: 11/29/2022]
Affiliation(s)
- Luca Pani
- Italian Medicines Agency (AIFA), Via del Tritone 181, 00187 Rome, Italy; National Health Insurance Fund Administration (OEP), Váciút 73/A, H-1139 Budapest, Hungary; Italian Medicines Agency (AIFA), Via del Tritone 181, 00187 Rome, Italy; WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Gesundheit Österreich GmbH (Austrian Public Health Institute), Stubenring 6, 1010 Vienna, Austria.
| | - Simona Montilla
- Italian Medicines Agency (AIFA), Via del Tritone 181, 00187 Rome, Italy; National Health Insurance Fund Administration (OEP), Váciút 73/A, H-1139 Budapest, Hungary; Italian Medicines Agency (AIFA), Via del Tritone 181, 00187 Rome, Italy; WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Gesundheit Österreich GmbH (Austrian Public Health Institute), Stubenring 6, 1010 Vienna, Austria.
| | - Gergely Németh
- Italian Medicines Agency (AIFA), Via del Tritone 181, 00187 Rome, Italy; National Health Insurance Fund Administration (OEP), Váciút 73/A, H-1139 Budapest, Hungary; Italian Medicines Agency (AIFA), Via del Tritone 181, 00187 Rome, Italy; WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Gesundheit Österreich GmbH (Austrian Public Health Institute), Stubenring 6, 1010 Vienna, Austria.
| | - Pierluigi Russo
- Italian Medicines Agency (AIFA), Via del Tritone 181, 00187 Rome, Italy; National Health Insurance Fund Administration (OEP), Váciút 73/A, H-1139 Budapest, Hungary; Italian Medicines Agency (AIFA), Via del Tritone 181, 00187 Rome, Italy; WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Gesundheit Österreich GmbH (Austrian Public Health Institute), Stubenring 6, 1010 Vienna, Austria.
| | - Giorgia Viceconte
- Italian Medicines Agency (AIFA), Via del Tritone 181, 00187 Rome, Italy; National Health Insurance Fund Administration (OEP), Váciút 73/A, H-1139 Budapest, Hungary; Italian Medicines Agency (AIFA), Via del Tritone 181, 00187 Rome, Italy; WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Gesundheit Österreich GmbH (Austrian Public Health Institute), Stubenring 6, 1010 Vienna, Austria.
| | - Sabine Vogler
- Italian Medicines Agency (AIFA), Via del Tritone 181, 00187 Rome, Italy; National Health Insurance Fund Administration (OEP), Váciút 73/A, H-1139 Budapest, Hungary; Italian Medicines Agency (AIFA), Via del Tritone 181, 00187 Rome, Italy; WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Gesundheit Österreich GmbH (Austrian Public Health Institute), Stubenring 6, 1010 Vienna, Austria.
| |
Collapse
|
10
|
Bernardini C, Muscolo LAA, Siviero PD, Montilla S, Pani L. Are we ready? What is missing and what is needed? A regulator’s perspective. Orphanet J Rare Dis 2014. [PMCID: PMC4249619 DOI: 10.1186/1750-1172-9-s1-o25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
11
|
Montilla S, Marchesini G, Sammarco A, Trotta MP, Siviero PD, Tomino C, Melchiorri D, Pani L. Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry. Nutr Metab Cardiovasc Dis 2014; 24:1346-1353. [PMID: 25300980 DOI: 10.1016/j.numecd.2014.07.014] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/04/2013] [Revised: 07/14/2014] [Accepted: 07/16/2014] [Indexed: 02/08/2023]
Abstract
BACKGROUND AND AIMS In Italy, the reimbursed use of incretin mimetics and incretin enhancers was subject to enrollment of patients into a web-based system recording the general demographic and clinical data of patients. We report the utilization data of glucagon-like peptide 1 (GLP1) receptor agonists and dipeptidylpeptidase-4 (DPP4) inhibitors in clinical practice as recorded by the Italian Medicines Agency (AIFA) Monitoring Registry. METHODS AND RESULTS From February 2008 to August 2010, 75,283 patients with type 2 diabetes were entered into the registry and treated with exenatide, sitagliptin, or vildagliptin. The treatment was administered to patients in a wide range of ages (≥75 years, n = 6125 cases), body mass index (BMI) (≥35 kg/m(2), n = 22,015), and metabolic control (HbA(1c) ≥ 11% ((96 mmol/mol), n = 3151). Overall, 1116 suspected adverse drug reactions were registered, including 12 cases of acute pancreatitis (six on exenatide). Hypoglycemic episodes mainly occurred in combination with sulfonylureas. Treatment discontinuation for the three drugs (logistic regression analysis) was negatively associated with the male gender and positively with baseline HbA1c, diabetes duration, and, limitedly to DPP-4 inhibitors, with BMI. Treatment discontinuation (including loss to follow-up, accounting for 21-26%) was frequent. Discontinuation for treatment failure occurred in 7.7% of cases (exenatide), 3.8% (sitagliptin), and 4.1% (vildagliptin), respectively, corresponding to 27-40% of all discontinuations, after excluding lost to follow-up. HbA1c decreased on average by 0.9-1.0% (9 mmol/mol). Body weight decreased by 3.5% with exenatide and by 1.0-1.5% with DPP-4 inhibitors. CONCLUSIONS In the real world of Italian diabetes centers, prescriptions of incretins have been made in many cases outside the regulatory limits. Nevertheless, when appropriately utilized, incretins may grant results at least in line with pivotal trials.
Collapse
Affiliation(s)
- S Montilla
- Italian Medicines Agency (AIFA), Rome, Italy.
| | - G Marchesini
- Unit of Metabolic Diseases, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - A Sammarco
- Italian Medicines Agency (AIFA), Rome, Italy
| | - M P Trotta
- Italian Medicines Agency (AIFA), Rome, Italy
| | - P D Siviero
- Italian Medicines Agency (AIFA), Rome, Italy
| | - C Tomino
- Italian Medicines Agency (AIFA), Rome, Italy
| | - D Melchiorri
- Dept. Physiology and Pharmacology, University of Rome "La Sapienza", Rome, Italy
| | - L Pani
- Italian Medicines Agency (AIFA), Rome, Italy
| |
Collapse
|
12
|
|
13
|
Pani L, Montilla S, Pimpinella G, Bertini Malgarini R. Biosimilars: the paradox of sharing the same pharmacological action without full chemical identity. Expert Opin Biol Ther 2013; 13:1343-6. [DOI: 10.1517/14712598.2013.815722] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
14
|
Caro E, Montilla S, Castañeda C, León J, Quintana P, Saez L. 24. Neurophysiological changes in coeliac disease: A case study. Clin Neurophysiol 2009. [DOI: 10.1016/j.clinph.2008.09.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
15
|
Castañeda C, Botella L, Caro E, León J, Montilla S, Paradinas F, Escobar-Morreale H, Galan J. 16. Evoked potentials in patients with differentiated thyroid carcinoma before and during levothyroxine withdrawal. Clin Neurophysiol 2009. [DOI: 10.1016/j.clinph.2008.09.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
16
|
León J, Montilla S, Salinas M, Gobernado J, Lousa M, de Blas G. 37. Multifocal motor demyelinating neuropathy: A case report. Clin Neurophysiol 2009. [DOI: 10.1016/j.clinph.2008.09.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
Abstract
In Italy the price setting of medicines reimbursed by the National Health Service is regulated at the central level by AIFA, the national regulatory authority. Prices of non reimbursed medicines are indeed freely established, with some limitations, by pharmaceutical companies. To contain pharmaceutical expenditure and rationalise the whole sector the following measures have been introduced in the past years: a threshold to public pharmaceutical expenditure (PPE); a reference price system (RPS) for off-patent medicines; a pay-back mechanism as an alternative to price cut. In 2008 Italy launched a reform of the pharmaceutical expenditure governance system with the aim to introduce stability and promote development and competitiveness in the pharmaceutical sector.
Collapse
|
18
|
Mazzei F, Botrè F, Montilla S, Pilloton R, Podestà E, Botrè C. Alkaline phosphatase inhibition based electrochemical sensors for the detection of pesticides. J Electroanal Chem (Lausanne) 2004. [DOI: 10.1016/j.jelechem.2004.08.004] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
19
|
Botrè C, Botrè F, Mazzei F, Montilla S, Podestà E. Some considerations on the kinetics of pathogenic prions formation. Ann Ist Super Sanita 2002; 38:195-8. [PMID: 12387144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/26/2023]
Abstract
Literature data, respective to kinetics of infectivities due to prion diseases, have been here reconsidered. The autocatalytic phenomenon of prion replication and the process of advancement of the infection are also considered. A model describing the interconversion from "normal" into "pathogenic" prions, and the subsequent growth of the infection, is proposed. This model takes into account the existence of two different steps: the first, slower, in which the interaction between the two different prions, with the transformation of normal prions into the pathogen ones, takes place. The second one, very fast, in which the degree of advancement of the infection assumes the form of an irreversible, rapid trend.
Collapse
Affiliation(s)
- Claudio Botrè
- Dipartimento di Farmacologia delle Sostanze Naturali e Fisiologia Generale, Università degli Studi La Sapienza, Piazzale Aldo Moro 5, 00185 Roma.
| | | | | | | | | |
Collapse
|
20
|
Ginestal RC, Martínez-Castrillo JC, Sánchez-Bueno C, Callejo JM, Herrero A, Montilla S, Alvarez-Cermeño JC. [Thrombosis of the vertebral artery, shown on angioresonance, in the lateral bulbar syndrome]. Rev Neurol 2002; 34:351-4. [PMID: 12022051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
INTRODUCTION The lateral bulbar syndrome is a heterogeneous clinical condition. It is usually of vascular origin, due to a reduction in postero inferior cerebellar artery (PICA) and vertebral artery blood flow. CASE REPORT We studied two cases: a woman aged 59 years and a man of 49 years, who were admitted with Wallenberg s syndrome. The diagnosis was confirmed on magnetic resonance which showed an ischaemic lesion in the lateral bulbar region ipsilateral to the clinical signs. On angioresonance there was lack of filling of the vertebral artery involved, and the PICA was not seen. CONCLUSIONS At the present time, the most sensitive technique available for the diagnosis of the lateral bulbar syndrome is cranial magnetic resonance (it even appears to be useful for making aetiopathogenic hypotheses). Similarly, arteriography is widely used for assessing disorders of the posterior cerebral circulation, although it is not without risk. According to recent studies, angioresonance gives sensitivity and specificity of over 75% when used to assess anomalies of the vertebral and basilar arteries. So our observations corroborate the finding that angioresonance is a very sensitive, specific investigation for showing disorders of the vertebral arteries and PICA, which spares patients the morbidity associated with conventional arteriography.
Collapse
Affiliation(s)
- R C Ginestal
- Servicio de Neurología; Hospital Ramón y Cajal. Facultad de Medicina, Madrid, 28034, España
| | | | | | | | | | | | | |
Collapse
|